Literature DB >> 6333639

Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation.

K Hui, F Grosveld, H Festenstein.   

Abstract

Major histocompatibility complex (MHC) class I molecules can function as specific target antigens in T-cell-mediated cytotoxity. In addition, T cells can kill target cells through non-MHC antigens, for example, virally infected cells, if the target and effector cells express the same MHC class I antigens. Consequently, quantitative and/or qualitative variations in the expression of the H-2/HLA antigens on the target cells could interfere with MHC-restricted immune reactions. We have reported that the AKR leukaemia cell line K36.16, a subline of K36 (ref. 3), on which the H-2Kk antigen cannot be detected, is resistant to T-cell lysis and grows very easily in AKR mice. Other AKR tumour cell lines, like 369, which have a relatively large amount of H-2Kk on their surface, are easily killed by T cells in vitro and require a much larger inoculum to grow in vivo. Monoclonal antibodies against H-2Kk, but not against H-2Dk, prevented the killing by T cells. This suggests that some tumour cells grow in vivo because tumour-associated antigen(s) cannot be recognized efficiently by the host's immune system, due to the absence of MHC molecules which would function as restriction elements for T-cell cytotoxicity. We have tested this hypothesis by introducing the H-2Kk gene into the H-2Kk-deficient AKR tumour cell line K36.16 and have now demonstrated directly the biological relevance of H-2Kk antigen expression in the regulation of the in vivo growth of this tumour cell line.

Entities:  

Mesh:

Year:  1984        PMID: 6333639     DOI: 10.1038/311750a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  77 in total

1.  Alterations of class I HLA genes in human colon cancers.

Authors:  M Bar-Eli; H Battifora; M J Cline
Journal:  Hum Genet       Date:  1988-01       Impact factor: 4.132

Review 2.  Cancer of the cervix: prospects for immunological control.

Authors:  D H Davies; G A McIndoe; B M Chain
Journal:  Int J Exp Pathol       Date:  1991-04       Impact factor: 1.925

Review 3.  Class I genes and molecules: an update.

Authors:  A M Lew; E P Lillehoj; E P Cowan; W L Maloy; M R van Schravendijk; J E Coligan
Journal:  Immunology       Date:  1986-01       Impact factor: 7.397

4.  Developmental and tissue-specific regulation of the Q10 class I gene by DNA methylation.

Authors:  K Tanaka; Y Barra; K J Isselbacher; G Khoury; G Jay
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

Review 5.  Gene therapy for carcinoma of the breast.

Authors:  M A Stoff-Khalili; P Dall; D T Curiel
Journal:  Cancer Gene Ther       Date:  2006-01-06       Impact factor: 5.987

6.  Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo.

Authors:  T Aoki; K Tashiro; S Miyatake; T Kinashi; T Nakano; Y Oda; H Kikuchi; T Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

Review 7.  Adequate antigen availability: a key issue for novel approaches to tumor vaccination and tumor immunotherapy.

Authors:  Roberto S Accolla; Giovanna Tosi
Journal:  J Neuroimmune Pharmacol       Date:  2012-12-07       Impact factor: 4.147

8.  Autocrine induction of major histocompatibility complex class I antigen expression results from induction of beta interferon in oncogene-transformed BALB/c-3T3 cells.

Authors:  M K Offermann; D V Faller
Journal:  Mol Cell Biol       Date:  1989-05       Impact factor: 4.272

9.  Regulated expression of a murine class I gene in transgenic mice.

Authors:  C Bieberich; G Scangos; K Tanaka; G Jay
Journal:  Mol Cell Biol       Date:  1986-04       Impact factor: 4.272

10.  Retroviral transduction of interferon-gamma cDNA into a nonimmunogenic murine fibrosarcoma: generation of T cells in draining lymph nodes capable of treating established parental metastatic tumor.

Authors:  E Shiloni; S E Karp; M C Custer; J Shilyansky; N P Restifo; S A Rosenberg; J J Mulé
Journal:  Cancer Immunol Immunother       Date:  1993-10       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.